Marker Therapeutics, Inc.
MRKRNasdaqCIK 1094038HealthcareFiscal year ends Dec 31
Reports and events: 307 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1911:12 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-116720 |
| 2026-08-1420:35 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-097262 |
| 2026-05-1521:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-062763 |
| 2026-05-0420:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-054940 |
| 2026-03-2020:05 ET | DEF 14A | Proxy statementPeriod 2026-05-01 | 0001104659-26-032694 |
| 2026-03-1921:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-031309 |
| 2026-03-1821:26 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-031274 |
| 2026-02-0921:06 ET | 8-K | 5.08 Item not in the standard list; 9.01 Financial statements and exhibits | 0001104659-26-012063 |
| 2025-11-1721:22 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000858 |
| 2025-11-1412:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-111940 |
| 2025-11-1322:29 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-111502 |
| 2025-11-0512:36 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-106669 |
| 2025-10-0611:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-096935 |
| 2025-08-2611:16 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-082783 |
| 2025-08-2020:58 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-080957 |
| 2025-08-1918:42 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-080213 |
| 2025-08-1821:34 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000647 |
| 2025-08-1421:16 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001410578-25-001826 |
| 2025-08-1220:08 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001104659-25-076834 |
| 2025-06-1712:00 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-060092 |
| 2025-06-0920:13 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-25-057836 |
| 2025-05-2012:32 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-050771 |
| 2025-05-1521:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001410578-25-001342 |
| 2025-04-2420:42 ET | DEF 14A | Proxy statementPeriod 2025-06-06 | 0001104659-25-038633 |
| 2025-03-3112:48 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-029666 |
| 2025-03-3112:18 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001410578-25-000549 |
| 2025-03-2721:00 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-028821 |
| 2025-03-0422:08 ET | 8-K/A | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001104659-25-020405 |
| 2025-02-1922:02 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001104659-25-015224 |
| 2025-02-0421:05 ET | DEF 14A | Proxy statementPeriod 2025-03-21 | 0001104659-25-009098 |
| 2025-01-3021:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-007574 |
| 2024-12-2321:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-24-131322 |
| 2024-12-2321:30 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-24-000928 |
| 2024-12-1913:21 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-130002 |
| 2024-12-1712:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-129181 |
| 2024-11-1421:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-119077 |
| 2024-11-1421:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001410578-24-001978 |
| 2024-08-1420:47 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-089704 |
| 2024-08-1420:39 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001410578-24-001454 |
| 2024-08-1211:12 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-088054 |
| 2024-06-1220:05 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events | 0001104659-24-070830 |
| 2024-05-1722:25 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-24-000515 |
| 2024-05-1520:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-062001 |
| 2024-05-1520:03 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001410578-24-000865 |
| 2024-04-2620:05 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0001104659-24-052914 |
| 2024-04-0811:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-044496 |
| 2024-03-2622:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-038533 |
| 2024-03-2621:37 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001410578-24-000297 |
| 2024-03-0113:02 ET | 8-K | 1.02 Termination of a material agreement | 0001104659-24-029638 |
| 2024-02-2612:58 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-24-027293 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.